RESUMEN
We evaluated 52 different E. coli expressed pneumococcal proteins as immunogens in a BALB/c mouse model of S. pneumoniae lung infection. Proteins were selected based on genetic conservation across disease-causing serotypes and bioinformatic prediction of antibody binding to the target antigen. Seven proteins induced protective responses, in terms of reduced lung burdens of the serotype 3 pneumococci. Three of the protective proteins were histidine triad protein family members (PhtB, PhtD and PhtE). Four other proteins, all bearing LPXTG linkage domains, also had activity in this model (PrtA, NanA, PavB and Eng). PrtA, NanA and Eng were also protective in a CBA/N mouse model of lethal pneumococcal infection. Despite data inferring widespread genomic conservation, flow-cytometer based antisera binding studies confirmed variable levels of antigen expression across a panel of pneumococcal serotypes. Finally, BALB/c mice were immunized and intranasally challenged with a viulent serotype 8 strain, to help understand the breadth of protection. Those mouse studies reaffirmed the effectiveness of the histidine triad protein grouping and a single LPXTG protein, PrtA.
Asunto(s)
Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Secuencia Conservada , Pruebas Genéticas , Neumonía Neumocócica/prevención & control , Streptococcus pneumoniae/inmunología , Animales , Antígenos Bacterianos/genética , Carga Bacteriana , Proteínas Bacterianas/genética , Clonación Molecular , Biología Computacional , Modelos Animales de Enfermedad , Escherichia coli/genética , Femenino , Expresión Génica , Pulmón/microbiología , Ratones Endogámicos BALB C , Ratones Endogámicos CBA , Neumonía Neumocócica/microbiología , Streptococcus pneumoniae/genética , Análisis de SupervivenciaRESUMEN
BACKGROUND: We evaluated the immunological responses of African green monkeys immunized with multiple F and G protein-based vaccines and assessed protection against the Memphis 37 strain of respiratory syncytial virus (RSV). METHODS: Monkeys were immunized with F and G proteins adjuvanted with immunostimulatory (CpG) oligodeoxyribonucleotides admixed with either Alhydrogel or ISCOMATRIX adjuvant. Delivery of F and G proteins via replication incompetent recombinant vesicular stomatitis viruses (VSVs) and human adenoviruses was also evaluated. Mucosally or parenterally administered recombinant adenoviruses were used in prime-boost regimens with adjuvanted proteins or recombinant DNA. RESULTS: Animals primed by intranasal delivery of recombinant adenoviruses, and boosted by intramuscular injection of adjuvanted F and G proteins, developed neutralizing antibodies and F/G protein-specific T cells and were protected from RSV infection. Intramuscular injections of Alhydrogel (plus CpG) adjuvanted F and G proteins reduced peak viral loads in the lungs of challenged monkeys. Granulocyte numbers were not significantly elevated, relative to controls, in postchallenge bronchoalveolar lavage samples from vaccinated animals. CONCLUSIONS: This study has validated the use of RSV (Memphis 37) in an African green monkey model of intranasal infection and identified nonreplicating vaccines capable of eliciting protection in this higher species challenge model.
Asunto(s)
Infecciones por Virus Sincitial Respiratorio/prevención & control , Vacunas contra Virus Sincitial Respiratorio/farmacología , Virus Sincitiales Respiratorios/inmunología , Adenovirus Humanos/genética , Adenovirus Humanos/inmunología , Adyuvantes Inmunológicos/farmacología , Animales , Anticuerpos Antivirales/inmunología , Lavado Broncoalveolar/métodos , Chlorocebus aethiops , Granulocitos/inmunología , Granulocitos/virología , Inmunización/métodos , Pulmón/inmunología , Pulmón/virología , Distribución Aleatoria , Infecciones por Virus Sincitial Respiratorio/inmunología , Infecciones por Virus Sincitial Respiratorio/virología , Vacunas contra Virus Sincitial Respiratorio/genética , Vacunas contra Virus Sincitial Respiratorio/inmunología , Virus Sincitiales Respiratorios/genética , Linfocitos T/inmunología , Linfocitos T/virología , Vesiculovirus/genética , Vesiculovirus/inmunología , Proteínas Virales de Fusión/genética , Proteínas Virales de Fusión/inmunología , Carga Viral/inmunología , Proteínas Virales/genética , Proteínas Virales/inmunología , Replicación Viral/genética , Replicación Viral/inmunologíaRESUMEN
DNA vaccines expressing HSV-2 gD, gB, ICP27, VP22 and VP13/14 were shown to be immunogenic in mice; gD and gB elicited neutralising antibody, and all five antigens induced T cell responses measured by IFNγ ELISPOT. In murine HSV-2 challenge studies, gD and gB provided moderate to high levels of protection while ICP27 provided a lower level of protection depending on the model (intravaginal or intranasal) and the challenge dose. Combining vaccines expressing gB or gD with vaccines expressing ICP27 provided greater protection than any antigen alone. We conclude that the addition of ICP27 to enhance the anti-viral T cell response can improve the efficacy of gD- and gB-based vaccines.
Asunto(s)
Infecciones por Herpesviridae/prevención & control , Herpesvirus Humano 2/inmunología , Vacunas contra Herpesvirus/inmunología , Proteínas Inmediatas-Precoces/inmunología , Vacunas de ADN/inmunología , Proteínas del Envoltorio Viral/inmunología , Proteínas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Modelos Animales de Enfermedad , Femenino , Infecciones por Herpesviridae/inmunología , Infecciones por Herpesviridae/patología , Herpesvirus Humano 2/genética , Vacunas contra Herpesvirus/administración & dosificación , Proteínas Inmediatas-Precoces/genética , Ratones , Ratones Endogámicos BALB C , Índice de Severidad de la Enfermedad , Linfocitos T/inmunología , Vacunas de ADN/administración & dosificación , Proteínas del Envoltorio Viral/genética , Proteínas Virales/genéticaRESUMEN
The efficacy of multi-agent DNA vaccines consisting of a truncated gene encoding Bacillus anthracis lethal factor (LFn) fused to either Yersinia pestis V antigen (V) or Y . pestis F1 was evaluated. A/J mice were immunized by gene gun and developed predominantly IgG1 responses that were fully protective against a lethal aerosolized B. anthracis spore challenge but required the presence of an additional DNA vaccine expressing anthrax protective antigen to boost survival against aerosolized Y. pestis.
Asunto(s)
Vacunas contra el Carbunco/inmunología , Carbunco/prevención & control , Vacuna contra la Peste/inmunología , Peste/prevención & control , Animales , Carbunco/inmunología , Carbunco/mortalidad , Vacunas contra el Carbunco/administración & dosificación , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Antígenos Bacterianos/genética , Antígenos Bacterianos/inmunología , Bacillus anthracis/inmunología , Bacillus anthracis/patogenicidad , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , Toxinas Bacterianas/genética , Toxinas Bacterianas/inmunología , Biolística , Inmunización , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Ratones , Peste/inmunología , Peste/mortalidad , Vacuna contra la Peste/administración & dosificación , Proteínas Citotóxicas Formadoras de Poros/genética , Proteínas Citotóxicas Formadoras de Poros/inmunología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Esporas Bacterianas/inmunología , Esporas Bacterianas/patogenicidad , Tasa de Supervivencia , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología , Yersinia pestis/inmunologíaRESUMEN
In this paper we evaluate the role of human γδ T cells in control of Francisella tularensis infection. Using an in vitro model of infection, a reduction in bacterial numbers was detected in the presence of human γδ T cells for both attenuated LVS and virulent SCHU S4 strains of F. tularensis. Antibody neutralisation of IFN-γ caused an increase in survival of F. tularensis LVS suggesting that γδ T cell-mediated control of F. tularensis infection is partially mediated by IFN-γ.
Asunto(s)
Francisella tularensis/inmunología , Francisella tularensis/patogenicidad , Receptores de Antígenos de Linfocitos T gamma-delta/inmunología , Linfocitos T/inmunología , Tularemia/inmunología , Tularemia/microbiología , Células Cultivadas , Francisella tularensis/clasificación , Humanos , Receptores de Interferón/metabolismo , Especificidad de la Especie , Receptor de Interferón gammaRESUMEN
As there is currently no licensed vaccine against Francisella tularensis, the causative agent of tularaemia, the bacterium is an agent of concern as a potential bioweapon. Although F. tularensis has a low infectious dose and high associated mortality, it possesses few classical virulence factors. An analysis of the F. tularensis subspecies tularensis genome sequence has revealed the presence of a region containing genes with low sequence homology to part of the capBCADE operon of Bacillus anthracis. We have generated an isogenic capB mutant of F. tularensis subspecies tularensis SchuS4 and shown it to be attenuated. Furthermore, using BALB/c mice, we have demonstrated that this capB strain affords protection against significant homologous challenge with the wild-type strain. These data have important implications for the development of a defined and efficacious tularaemia vaccine.
Asunto(s)
Vacunas Bacterianas/inmunología , Francisella tularensis/genética , Eliminación de Secuencia , Tularemia/prevención & control , Factores de Virulencia/genética , Secuencia de Aminoácidos , Animales , Bacillus anthracis/genética , Vacunas Bacterianas/genética , Biología Computacional , Femenino , Genes Bacterianos , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Operón , Alineación de Secuencia , Homología de Secuencia , Análisis de Supervivencia , Vacunas Atenuadas/genética , Vacunas Atenuadas/inmunología , VirulenciaRESUMEN
Antibodies can be used to confer rapid immunity against infectious agents for short periods of time. By comparison, vaccine induced immunity is more protective, but takes a relatively long time to develop. Concomitant administration of antibody and vaccine by different routes was evaluated as a means of providing both rapid and long-term protection against plague. BALB/c mice were treated intraperitoneally with monoclonal antibodies, with specificities for Yersinia pestis LcrV and F1 antigens. A cohort of these mice was simultaneously vaccinated with rF1 and rLcrV by the intramuscular route. Antibody co-administration with vaccine reduced the level of vaccine mediated protection afforded against a high level Y. pestis challenge. Conversely, antibody-mediated protection was unaffected by vaccine co-administration and lasted for at least 8 weeks post administration. We also evaluated the effect of administering vaccine intradermally and antibody intratracheally and observed that, irrespective of administration route, concomitant administration of antibody reduced the effectiveness of vaccine mediated immunity. The results of passive transfer experiments supported the thesis that the development of protective antibody responses following vaccination is impaired by the presence of circulating monoclonal antibodies with specificities for important B-cell epitopes in the vaccine. We also noted that intradermal injection of LcrV antigen and cholera toxin adjuvant afforded good levels of protection against systemic and aerosol challenge with Y. pestis: intradermal injection might therefore be considered as a potential minimally invasive method of plague vaccine administration. These data have implications for the design of therapeutic strategies against plague infection.
Asunto(s)
Anticuerpos Antibacterianos/administración & dosificación , Anticuerpos Monoclonales/administración & dosificación , Vacuna contra la Peste/administración & dosificación , Vacuna contra la Peste/inmunología , Peste/inmunología , Peste/prevención & control , Yersinia pestis/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Animales , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/administración & dosificación , Antígenos Bacterianos/inmunología , Toxina del Cólera/administración & dosificación , Epítopos de Linfocito B , Femenino , Inmunización Pasiva , Ratones , Ratones Endogámicos BALB C , Proteínas Citotóxicas Formadoras de Poros/administración & dosificación , Proteínas Citotóxicas Formadoras de Poros/inmunología , Factores de TiempoRESUMEN
Major advances in our understanding of how the mammalian immune system recognises pathogens have evolved from initial observations of fruit-fly developmental mutants. Through this work it has been established that vertebrates possess a specialised 'early warning system' in the form of a panel of detectors to rapidly sense and trigger responses to the presence of microbial invaders through detection of so called pathogen-associated molecular patterns (PAMPs). This discovery has led to the search for new agonists and antagonists that can be used, therapeutically, for rational manipulation of the immune response. These efforts have already yielded several exciting new strategies to treat autoimmune, atopic, malignant and infectious disease. This review article provides an overview of the potential impact of these drugs on human medicine.
Asunto(s)
Bacterias/patogenicidad , Infecciones Bacterianas/fisiopatología , Infecciones Bacterianas/terapia , Sistema Inmunológico/efectos de los fármacos , Transducción de Señal/fisiología , Vacunas/inmunología , Vacunas/uso terapéutico , Animales , Humanos , Inmunidad/efectos de los fármacos , Vacunas/efectos adversosRESUMEN
Stimulation of protective immune responses against intracellular pathogens is difficult to achieve using non-replicating vaccines. BALB/c mice immunized by intramuscular injection with killed Francisella tularensis (live vaccine strain) adjuvanted with preformed immune stimulating complexes admixed with CpG, were protected when systemically challenged with a highly virulent strain of F. tularensis (Schu S4). Serum from immunized mice was used to probe a whole proteome microarray in order to identify immunodominant antigens. Eleven out of the top 12 immunodominant antigens have been previously described as immunoreactive in F. tularensis. However, 31 previously unreported immunoreactive antigens were revealed using this approach. Twenty four (50%) of the ORFs on the immunodominant hit list belonged to the category of surface or membrane associated proteins compared to only 22% of the entire proteome. There were eight hypothetical protein hits and eight hits from proteins associated with different aspects of metabolism. The chip also allowed us to readily determine the IgG subclass bias, towards individual or multiple antigens, in protected and unprotected animals. These data give insight into the protective immune response and have potentially important implications for the rational design of non-living vaccines for tularemia and other intracellular pathogens.
Asunto(s)
Francisella tularensis/inmunología , Epítopos Inmunodominantes/análisis , Análisis por Matrices de Proteínas/métodos , Proteómica/métodos , Adyuvantes Inmunológicos , Hidróxido de Aluminio/inmunología , Animales , Proteínas Bacterianas/inmunología , Proteínas Bacterianas/metabolismo , Femenino , Francisella tularensis/metabolismo , ISCOMs/inmunología , Epítopos Inmunodominantes/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Interferón gamma/metabolismo , Interleucina-2/metabolismo , Interleucina-4/metabolismo , Ratones , Ratones Endogámicos BALB C , Oligodesoxirribonucleótidos/inmunología , Proteoma/inmunología , Proteoma/metabolismo , Bazo/citología , Bazo/inmunología , Análisis de Supervivencia , Linfocitos T/inmunología , Linfocitos T/metabolismo , Tularemia/inmunología , Tularemia/microbiología , Tularemia/prevención & control , VacunaciónRESUMEN
Intratracheal delivery of aerosolized monoclonal antibodies with specificity for Yersinia pestis LcrV and F1 antigens protected mice in a model of pneumonic plague. These data support the utility of inhaled antibodies as a fast-acting postexposure treatment for plague.
Asunto(s)
Anticuerpos Antibacterianos/administración & dosificación , Anticuerpos Monoclonales/administración & dosificación , Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Peste/prevención & control , Yersinia pestis/inmunología , Aerosoles , Animales , Femenino , Ratones , Ratones Endogámicos BALB C , Proteínas Citotóxicas Formadoras de PorosRESUMEN
Certain toll-like receptor (TLR) agonists, e.g. CpG DNA, can be used as potent vaccine 'adjuvants'. It is known that some sequences of single stranded (ss) RNA stimulate proinflammatory and antiviral responses following interaction with TLR 7 and 8. We have encapsulated ovalbumin (OVA) in the presence and absence of polyuridylic acid (poly-U) inside polylactide microparticles. In comparison to microparticles containing only OVA, bulk cultures of bone marrow-derived plasmacytoid and myeloid dendritic cells produced more (P<0.05) IL-12 and interferon (IFN)-alpha when stimulated with microparticles containing OVA and poly-U. Subcutaneous injection of comicroencapsulated OVA and poly-U resulted in statistically elevated levels of serum anti-OVA IgG1 (P<0.05 versus naïve mice). Conversely, anti-OVA IgG1 levels in C57 BL6 mice immunised with OVA loaded microparticles (without RNA) were statistically indifferent to naïve animals. Furthermore, injection of coencapsulated OVA and poly-U resulted in (P<0.05) greater numbers of OVA specific IFN-gamma secreting T-cells as compared with mice injected with OVA loaded microparticles. A similar trend was seen in mice immunised with OVA loaded microparticles decorated with CpG or solutions of admixed OVA and CpG (P<0.05). These data demonstrate, for the first time, that appropriately formulated ssRNA can act as a potent adjuvant and modulator of adaptive immunological responses.
Asunto(s)
Adyuvantes Inmunológicos , Ovalbúmina/inmunología , Poli U/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/farmacología , Animales , Anticuerpos/sangre , Células Dendríticas/inmunología , Composición de Medicamentos , Femenino , Inmunoglobulina G/sangre , Interferón-alfa/biosíntesis , Interleucina-12/biosíntesis , Ratones , Ratones Endogámicos C57BL , Microesferas , Oligodesoxirribonucleótidos/administración & dosificación , Oligodesoxirribonucleótidos/inmunología , Ovalbúmina/administración & dosificación , Poli U/administración & dosificación , Linfocitos T/inmunología , Receptores Toll-LikeRESUMEN
Expanding identification of potentially protective subunit antigens and correlates of protection has provided a basis for the introduction of safer vaccines. Despite encouraging results in animal models, the significant potential of particulate delivery systems in vaccine design has not yet translated into effective vaccines available for use in humans. This review article will focus on the current status of the development of particulate vaccines, mainly liposomes and bio-degradable polymers, against potential agents for biowarfare: plague, anthrax, botulinum, and smallpox; and filoviruses: Marburg and Ebola.
Asunto(s)
Carbunco/prevención & control , Vacunas Bacterianas/administración & dosificación , Botulismo/prevención & control , Sistemas de Liberación de Medicamentos/métodos , Peste/prevención & control , Viruela/prevención & control , Vacunas Virales/administración & dosificación , Animales , Materiales Biocompatibles , Guerra Biológica , Sustancias para la Guerra Química/envenenamiento , Humanos , Ácido Láctico , Liposomas , Ácido Poliglicólico , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros , Ricina/envenenamientoRESUMEN
ESAT-6 from Mycobacterium tuberculosis is an important T-cell antigen for cell-mediated immunity in the early phase of tuberculosis infection. Since the lung is the organ in which infection is initiated, immune responses in the lung play a significant role in restricting the initial infection with M. tuberculosis. The aim of the present study was to assess whether efficient cell-mediated immune responses in the lung and draining mediastinal lymph nodes could be stimulated by pulmonary administration of ESAT-6 encapsulated in poly(lactide) (PLA) microspheres. BALB/c mice were immunised intranasally on days 1, 28 and 56 with 2 microg microencapsulated ESAT-6. Cellular responses in the lungs, spleen and mediastinal lymph nodes (MLN) were characterised using ELISPOT and proliferation assays. Fluorescence activated cell sorting (FACS) was used to assess the expression of CD44 on CD4+ and CD8+ cells derived from the MLN of immunised animals. For comparison, groups of mice were immunised intranasally with soluble 'free' ESAT-6 or intramuscularly with ESAT-6 in Alhydrogel. Intranasal instillation of microencapsulated ESAT-6 induced greatest numbers of ESAT-6 specific IFN-gamma and IL-4 secreting cells in the lung and MLN (P<0.05). Similarly, ESAT-6 specific recall responses were strongest following intranasal immunisation of mice with microsphere encapsulated antigen (P<0.05). FACS demonstrated a higher proportion of T cells expressing CD44 in the MLN from mice immunised intranasally with microencapsulated ESAT-6. These data support the notion that the immune system is compartmentalised and responses are often strongest in compartments proximal to the site of vaccine application. Furthermore, our data indicate that, for efficient activation of cell-mediated responses, antigens must be presented to the immune system in an appropriate formulation.
Asunto(s)
Antígenos Bacterianos/administración & dosificación , Sistemas de Liberación de Medicamentos/métodos , Inmunización/métodos , Pulmón/inmunología , Mucosa Nasal/metabolismo , Administración Intranasal , Animales , Antígenos Bacterianos/inmunología , Proteínas Bacterianas , Citocinas/inmunología , Composición de Medicamentos , Femenino , Inmunidad Celular , Pulmón/efectos de los fármacos , Ganglios Linfáticos/inmunología , Activación de Linfocitos/inmunología , Recuento de Linfocitos , Ratones , Ratones Endogámicos BALB C , Microesferas , Mucosa Nasal/inmunología , Linfocitos T/inmunologíaRESUMEN
We have carried out an in vitro investigation into the mechanism by which microencapsulation enhances the immunogenicity of recombinant protective antigen (rPA) from Bacillus anthracis. Murine bone marrow derived dendritic cells (DC) were cocultured with soluble and microencapsulated rPA and the activation status of the cells monitored using FACS. As compared with soluble rPA, it was found that coculture of DC with rPA-loaded microparticles stimulated higher levels of MHC II, CD54, CD80 and CD86 expression (p<0.05). To investigate the longevity of antigen presentation, splenocytes from naïve mice were pulsed overnight with (3)H-thymidine following 1, 3 or 6 days coculture with DC transiently exposed to soluble or microencapsulated rPA. Splenocyte proliferation was more pronounced, and continued for a more protracted period, if the 'feeder' cells were exposed to microencapsulated antigen as compared with soluble antigen or 'empty' microspheres. To this end, our findings indicate that microsphere uptake increases the surface expression of MHC and co-stimulatory molecules on DC and can facilitate prolonged presentation of antigen to T-cells, possibly by acting as an intracellular depot.
Asunto(s)
Antígenos Bacterianos/inmunología , Toxinas Bacterianas/inmunología , Células Dendríticas/inmunología , Microesferas , Animales , Antígenos CD/análisis , Antígeno B7-1/análisis , Antígeno B7-2 , Proliferación Celular , Células Cultivadas , Femenino , Citometría de Flujo , Antígenos de Histocompatibilidad Clase II/análisis , Molécula 1 de Adhesión Intercelular/análisis , Glicoproteínas de Membrana/análisis , Ratones , Bazo/citologíaRESUMEN
We hypothesized that the addition of polymer to the surface of liposome/DNA complexes may potentially enhance in vivo delivery of plasmid DNA to antigen-presenting cells and thereby facilitate enhanced immune responses to encoded protein. BALB/c mice were immunized subcutaneously or intramuscularly three times with a total of 50 microg of the plasmid pRc/CMV-HBs(S) (ayw subtype) encoding for the hepatitis B surface antigen. We measured transgene-specific total immunoglobulin G (IgG), IgG2a, IgG2b and IgG1 antibody responses as well as splenocyte and T-cell proliferation and cytokine production upon re-stimulation following immunization. Modification of lipid/DNA complexes by the polymer precipitation method used here for the addition of poly(d,l-lactic acid) was found to be consistently and significantly more effective than either unmodified liposomal DNA or naked DNA in eliciting transgene-specific immune responses to plasmid-encoded antigen when administered by the subcutaneous route. In addition, the polymer-modified formulations delivered by this route were more effective than naked DNA delivered by the intramuscular route in inducing antibody responses (n=5, P<0.03). Our observations provide 'proof of principle' for the use of these multicomponent formulations, which offer potential for manipulation and increased transfection efficiency in vivo for the purposes of genetic immunization.
Asunto(s)
ADN Viral/administración & dosificación , Técnicas de Transferencia de Gen , Antígenos de Superficie de la Hepatitis B/inmunología , Liposomas , Animales , Anticuerpos Antivirales/biosíntesis , División Celular/inmunología , Células Cultivadas , Citocinas/biosíntesis , Femenino , Antígenos de Superficie de la Hepatitis B/genética , Inmunización/métodos , Inmunoglobulina G/biosíntesis , Ratones , Ratones Endogámicos BALB C , Polímeros , Bazo/inmunología , Linfocitos T/inmunología , Transgenes/inmunologíaRESUMEN
Existing licensed anthrax vaccines are administered parenterally and require multiple doses to induce protective immunity. This requires trained personnel and is not the optimum route for stimulating a mucosal immune response. Microencapsulation of vaccine antigens offers a number of advantages over traditional vaccine formulations, including stability without refrigeration and the potential for utilizing less invasive routes of administration. Recombinant protective antigen (rPA), the dominant antigen for protection against anthrax infection, was encapsulated in poly-L-lactide 100-kDa microspheres. Alternatively, rPA was loosely attached to the surfaces of microspheres by lyophilization. All of the microspheric formulations were administered to A/J mice with a two-dose schedule by either the intramuscular route, the intranasal route, or a combination of these two routes, and immunogenicity and protective efficacy were assessed. An intramuscular priming immunization followed by either an intramuscular or intranasal boost gave optimum anti-rPA immunoglobulin G titers. Despite differences in rPA-specific antibody titers, all immunized mice survived an injected challenge consisting of 10(3) median lethal doses of Bacillus anthracis STI spores. Immunization with microencapsulated and microsphere-associated formulations of rPA also protected against aerosol challenge with 30 median lethal doses of STI spores. These results show that rPA can be encapsulated and surface bound to polymeric microspheres without impairing its immunogenicity and also that mucosal or parenteral administration of microspheric formulations of rPA efficiently protects mice against both injected and aerosol challenges with B. anthracis spores. Microspheric formulations of rPA could represent the next generation of anthrax vaccines, which could require fewer doses because they are more potent, are less reactogenic than currently available human anthrax vaccines, and could be self-administered without injection.